For those who have not elected RRSO, which is the recommended risk management option for ovarian cancer in carriers of a pathogenic, likely pathogenic (P/LP) BRCA1/2 variant, TVUS and serum CA-125 may be considered at the clinician’s discretion starting at 30 to 35 years of age [38]. This evidence concerns the gene BRCA1 and ovarian carcinoma.